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Abstract 
Introduction: C1q/TNF-related Protein-3 (CTRP3) is a novel adipokine with multiple effects such as lowering glucose levels, inhibiting 
glyconeogenesis in the liver, and increasing angiogenesis and anti-inflammation. But little is known about the effects of CTRP3 on insu-
lin resistance in adipose tissue. This study aims to investigate the effects and mechanisms of CTRP3 on the insulin sensitivity of 3T3-L1 
adipocytes. 
Material and methods: Insulin resistant 3T3-L1 adipocytes were induced by palmic acid cultivation. Such adipocytes were treated with 
recombinant CTRP3 protein at different concentrations (0, 10, 50, 1,250 ng/mL）for 12 hours, and at a concentration of 250 ng/mL for differing 
times (2, 6, 12, and 24h). Another group was pre-treated with wortmannin, the special inhibitor of phosphatidylinositol-4,5- bisphosphate 
3-kinase (PI3K), for 20 minutes before the treatment with 250 ng/mL CTRP3. The glucose consumption, the glucose uptake, the expression 
and release of tumour necrosis factor α (TNF-α) and interleukin-6(IL-6) in supernatant, and the protein relative expression of PI3K and 
protein kinase B (PKB)(ser437) were detected. 
Results: Compared to the control group, glucose consumption in the CTRP3 intervention group at concentrations of 10, 50, 250, and 1,250 
ng/mL was increased by 22.1%, 42.9%, 76.6% and 80.5% respectively (all P < 0.01); the glucose uptake was increased by 39.0%, 68.0%, 
108.0% and 111.0% respectively (all P < 0.01); the content of TNF-α in the culture media of CTRP3 (10, 50, 250 ng/mL) intervention group 
was decreased by 7.6% (P > 0.05), 13.0% (P < 0.05) and 17.4% (P < 0.01) respectively; the content of IL-6 was decreased by 7.1%, 12.4% 
and 17.1% respectively (all P < 0.01); the protein relative expression of PI3K was increased by 0.63-, 1.00- and 1.36-fold respectively (all 
P < 0.01), and PKB(ser437) increased by 0.65-, 1.61- and 1.93-fold respectively (all P < 0.01); the mRNA relative expression of GLUT-4 was 
increased by 23.0%, 47.0% and 62.0% respectively (all P < 0.01). After the treatment with wortmannin, glucose consumption, glucose 
uptake, PI3K and PKB(ser437) protein relative expression, as well as GLUT-4 mRNA relative expression, was decreased by 53.2%, 44.7%, 
43.4%, 56.1 and 30.9% respectively (all P < 0.01). 
Conclusions: CTRP3 could improve insulin sensitivity of insulin resistant 3T3-L1 adipocytes by decreasing inflammation and ameliorating 
insulin signalling transduction, indicating that CTRP3 may be a new target for the prevention and cure of insulin resistance and type 2 
diabetes. (Endokrynol Pol 2014; 65 (4): 252–258)
 Key words: C1q/TNF related protein 3, insulin resistance, 3T3-L1 adipocytes, inflammation, insulin signalling transduction
Streszczenie
Wstęp: Białko związane z C1q/TNF typu 3 (CTRP3, C1q/TNF-related Protein-3) jest nowo odkrytą adipokiną o wielorakim działaniu obejmu-
jącym obniżenie stężenia glukozy we krwi, hamowanie glukoneogenezy w wątrobie, pobudzanie angiogenezy i działanie przeciwzapalne, 
Niewiele jednak wiadomo na temat wpływu CTRP3 na insulinooporność komórek tłuszczowych. Badanie to przeprowadzono w celu 
oceny mechanizmów działania tej adipokiny i jej wpływu na wrażliwość na insulinę adipocytów 3T3-L1.
Materiał i metody: Insulinooporne adipocyty 3T3-L1 uzyskano poprzez dodanie do hodowli tych komórek kwasu palmitynowego. Na-
stępnie adipocyty te poddano działaniu rekombinowanego białka CTRP3 w różnych stężeniach (0, 10, 50, 1250 ng/ml przez 12 godzin oraz 
w stężeniu 250 ng/ml przez różny czas (2, 6, 12, 24 godz.). Inną grupę hodowli komórkowych przed dodaniem CTRP3 w stężeniu 250 ng/ml 
inkubowano wstępnie z wortmaniną, inhibitorem kinazy fosfatydyloinozytolu-4,5 (PI3K, phosphatidylinositol-4,5- bisphosphate 3-kinase) przez 
20 minut. Określono zużycie glukozy, wychwyt glukozy, ekspresję i uwalnianie czynnika martwicy nowotworów typu alfa (TNF-α, tumor 
necrosis factor α) i interleukiny 6 (IL-6, interleukin-6,) w supernatancie oraz ekspresję PI3K i kinazy białkowej B (PKB, protein kinase B) (ser437). 
Wyniki: Zużycie glukozy w hodowlach poddanych działaniu CTRP3 w stężeniach 10, 50, 250, 1250 ng/ml było większe niż w hodowli 
kontrolnej odpowiednio o 22,1%, 42,9%, 76,6% i 80,5% (dla wszystkich porównań p < 0,01). Wychwyt glukozy był większy o 39,0%, 
68,0%, 108,0% i 111,0% (dla wszystkich porównań p < 0,01) Zawartości TNF-α w medium hodowli komórkowej z dodatkiem CTRP3 
(10, 50, 250 ng/ml) były mniejsze odpowiednio o 7,6% (p > 0,05), 13,0% (p < 0,05) i 17,4% (p < 0,01), a zawartości IL-6 były mniejsze 
o odpowiednio 7,1%, 12,4% i 17,1% (dla wszystkich porównań p < 0,01). Związana z białkami ekspresja PI3K stanowiła odpowiednio 0,63-, 
1,00- i 1,36-krotność wartości uzyskanej w hodowli kontrolnej (dla wszystkich porównań p < 0,01), a ekspresja PKB(ser437) stanowiła od-
powiednio 0,65-, 1,61- i 1,93-krotność (dla wszystkich porównań p < 0,01); Względna ekspresja mRNA GLUT-4 była większa odpowiednio 
o 23,0%, 47,0% i 62,0% (dla wszystkich porównań p < 0,01). W hodowlach poddanych wstępnie działaniu wortmaniny zużycie glukozy, 
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Introduction
Adipose tissue is the largest endocrine organ and 
secretes many bioactive molecules which are called 
adipokines, such as leptin, adiponectin, resistin, retinol-
binding protein 4, omentin, and vaspin. Adipokines, the 
levels of which are often dysregulated in conditions of 
obesity and/or diabetes, play important roles in insulin 
sensitivity and energy balance [1]. Much research has 
implicated adiponectin as a major insulin-sensitising 
adipokine as well as an important biomarker and thera-
peutic target for obesity-associated metabolic disorders 
[2]. However, the fact that there is only mild metabolic 
dysfunction in adiponectin knock-out mice indicates 
that there might be additional molecules with similar 
functions to adiponectin [3]. It was as a byproduct of 
discovering such metabolic regulators that led to the 
identification of C1q/TNF-related proteins 1–15 (CTRP 
1 to 15), which together with adiponectin belong to the 
C1q/TNF superfamily [4].
CTRP3 plays many roles in regulating inflammation 
and metabolism. Studies in vitro have indicated that 
recombinant human CTRP3 could reduce the secre-
tion of proinflammatory cytokine IL-6 and TNF-α in 
response to lipopolysaccharide stimulation in primary 
monocytes derived from healthy humans [5]. Studies 
in vivo have indicated that a modest three-fold eleva-
tion of plasma CTRP3 levels by recombinant protein 
administration in normal and insulin resistant ob/ob 
mice is sufficient to lower glucose levels which may 
be mediated by hepatic PKB activation and suppres-
sion of the expression of the gluconeogenic enzymes 
glucose-6-phosphatase and phosphoenolpyruvate 
carboxykinase [6]. A recent study showed that CTRP3 
attenuated diet-induced hepatic steatosis by regulat-
ing triglyceride metabolism [7], indicating that CTRP3 
was a very important regulator of glucose metabolism 
as well as lipid metabolism. Apart from this, previous 
studies also suggested that CTRP3 could be a novel 
antiapoptotic, proangiogenic, and cardioprotective 
adipokine, the expression of which is significantly 
inhibited after myocardial infarction [8].
Insulin resistance (IR) is the main and triggering 
factor in the pathogenesis of type 2 diabetes mellitus 
(T2DM). In obesity, there is chronic and low grade 
inflammation involved in the pathogenesis of T2DM, 
hypertension, atherosclerosis, fatty liver, cancer, asthma, 
and sleep apnoea [9]. Such inflammation starts mainly 
in adipose tissue with elevated macrophage infiltration 
and expression of proinflammatory cytokines. Inflam-
mation induces IR through several mechanisms, the 
most important of which is the inhibition of insulin 
signalling transduction [10]. As mentioned above, 
CTRP3 has beneficial effects on the metabolism of glu-
cose and fat as well as chronic low grade inflammation, 
yet the effect of CTRP3 on IR is largely unknown. So 
the present study aimed to investigate the effects and 
mechanisms of CTRP3 on the insulin sensitivity of 3T3-
L1 adipocytes with IR. 
Material and methods
Adipocyte cell culture
3T3-L1 preadipocytes (ATCC) were cultured at a 5% CO2 
atmosphere at 37 °C in DMEM (Gibco) supplemented 
with 10% newborn calf serum (Sigma) and penicil-
lin/streptomycin (GIBCO). At confluence, the cells 
were differentiated into adipocytes by treating them 
with DMEM/F12/glutamate-medium supplemented 
with 0.5 mmol/L 3-isobutyl-methyl-xanthine (IBMX), 
0.25 μmol/L corticosterone, 1 μmol/L insulin, 
200 μmmol/L ascorbate, 2 μg/mL transferrin, 1 μmmol/L bio-
tin, 17 μmmol/L panthothenate, and 300 mg/L Pedersen-
fetuin for five days. Thereafter, the cells were exposed 
to DMEM/F12/glutamate medium with 1nmol/L insulin 
until they reached the fully differentiated phenotype.
Insulin resistant adipocytes construction  
and assessment 
The differentiated adipocytes were incubated with 
Krebs-Ringer phosphate buffer (KRP) (pH 7.6) con-
taining 10 nm glucose, 1 mm palmitic acid PA), and 
1% BSA at 37°. Control cells were treated identically 
except that BSA without fatty acid was added to the 
KRP buffer. The duration of incubation was overnight 
for 3T3-L1 adipocytes. The incubation buffer was re-
moved and cells were resuspended for another hour 
at 37°, with KRP (pH 7.0) containing 1 mm pyruvate 
and 1% BSA without fatty acid. Cells were then washed 
twice with KRP (pH 7.6) containing 1% BSA without 
fatty acid and resuspended in appropriate buffers 
for experimentation. To evaluate insulin resistance, 
the glucose consumption and glucose uptake were 
detected. Adipocytes treated with PA showed signifi-
wychwyt glukozy, ekspresja PI3K i PKB(ser437) oraz ekspresja mRNA GLUT-4 były mniejsze odpowiednio o 53,2%, 44,7%, 43,4%, 56,1% 
i 30,9% (dla wszystkich porównań p < 0,01).
Wnioski: Białko CTRP3 może powodować zwiększenie wrażliwości na insulinę insulinoopornych adipocytów 3T3-L1 przez hamowanie 
procesu zapalnego i poprawę przewodzenia sygnałów insulinowych, co wskazuje, że białko to może być nowym celem w zapobieganiu 
i leczeniu insulinooporności i cukrzycy typu 2. (Endokrynol Pol 2014; 65 (4): 253–258)
Słowa kluczowe: białko związane z C1q/TNF typu 3; insulinooporność; adipocyty 3T3-L1; zapalenie; przekazywanie sygnałów insulinowych
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cantly lower glucose consumption and glucose uptake 
than untreated cells, and were considered to be insulin 
resistant. These insulin-resistant cells were used for the 
subsequent experiments.
Intervention 
The insulin resistant adipocytes were given recom-
binant CTRP3 protein (Jiahui, China) at different 
concentrations (0, 10, 50, 250, and 1,250 ng/mL) for 
12h, together with DMEM containing 25 mmol/L glu-
cose. To investigate the role of insulin signal molecule 
PI3K in the effects of CTRP3 on insulin resistant adipo-
cytes, 100 nmol/L wortmannin, the special inhibitor of 
PI3K, pre-treated the cells for 20 min before the treat-
ment with 250 ng/mL CTRP3 in another group. 
Detection
Glucose consumption
Glucose level in the cell culture media was determined 
by glucose oxidase method (Beihua Kangtai,China) and 
glucose consumption was calculated as (25-glucose 
level) mmol/L. 
Glucose uptake assay
Differentiated 3T3-L1 cells were induced with various 
concentrations of CTRP3 in the presence or absence 
of 10 nmol/L insulin for 30 min. After induction, cells 
were washed with KRP buffer and glucose uptake 
was initiated by the addition of 0.5  ml KRP buffer 
with 0.5 μCi 2-deoxy-d-[3H]-glucose (Kailong, China). 
Glucose uptake was terminated after 10 min by wash-
ing the cells with ice-cold PBS buffer three times. Cells 
were solubilised with 1ml NaOH (0.1mmol/L) for 
two hours and were counted by a liquid scintillation 
counter after being kept in the dark in scintillation 
fluid for 12h. Nonspecific uptake, determined in the 
presence of 10 μmol/L cytochalasin b, was subtracted 
from all values. 
Inflammation factors secretion
The concentration of TNF-α and IL-6 in the cell culture 
media was measured by Enzyme Linked Immunosorb-
ent Assay (Zhongzhi, China). Each sample was meas-
ured in duplicate.
Real-time-PCR Analysis (RT-PCR)
RNAs were isolated from 3T3-L1 adipocytes using 
TRIzol (Promega) and reverse transcribed using Su-
perscript II RNase H-reverse transcriptase (Invitrogen) 
according to the manufacturer’s protocol. PCR primers 
(Saibaisheng, China) used in the study were as follows: 
(1) IL-6: Sense 5-AGT TGC CTT CTT GGG ACT GA-3; 
Anti-sense: 5-CAG AAT TGC CAT TGC ACA AC-3; (2) 
TNF-α: Sense 5-ACG GCA TGG ATC TCA AAG AC-3; 
Anti-sense: CGG CAG AGA CCA CCT TGA ACT-3; (3) 
GLUT-4: Sense 5-CCC CGC TGG AAT GAG GTT TTT 
GAG GTG AT-3; Anti-sense: CAG ACA GGG GCC GAA 
GAT TGG GAG ACA GT-3; (4)β-actin: Sense 5-ACA CCC 
GCC ACC AGT TCG C-3; Anti-sense 5-TCT CCC CCT 
CAT CAC CCA CAT-3.
Western blot analysis
The cultured cells were washed twice with PBS, 
harvested gently with a cell scraper, centrifuged, 
and resuspended in 100 μl PBS. Whole cell proteins 
were extracted from 3T3-L1 adipocyte cells using 
lysis buffer (20 mmol/L MOPS, pH 7.0, 2 mmol/L 
EGTA, 5 mmol/L EDTA, 30 mmol/L sodium fluoride, 
40 mmol/L ß-glycerophosphate, 10 mmol/L sodium 
pyrophosphate, 2 mmol/L sodium orthovanadate, 
1 mmol/L phenylmethylsulfonyl fluoride, 3 mmol/L 
benzamidine, 5 μmol/L pepstatin A, 10 μmol/L leupep-
tin, 0.5% nonidet P-40, and 0.5% Triton X-100). Samples 
were boiled for 5 min in SDS loading buffer and equal 
amounts (25–50 μg per sample) of protein extracts 
were then separated by 8–12% of SDS-PAGE and 
electrotransferred onto PVDF membrane (Bio-Rad). 
Membranes were blocked with 5% non-fat skimmed 
milk in Tris-buffered saline/0.1% Tween20 (TBS-T) for 
1 h, and then incubated with affinity-purified goat 
polyclonal primary antibodies were used at the fol-
lowing working dilutions: PI3K (1:1,000 dilution); 
beta-actin: (1: 1,000 dilution) and PKB(Ser473): (1:1,000 
dilution). Appropriate secondary antibodies conju-
gated to horseradish peroxidase were incubated with 
respective membranes for 1 h at room temperature. 
Following five intermittent washes with 1 × TBS-T, the 
membranes was processed for autoradiography using 
enhanced chemiluminescence (ECL, Pierce Chemical). 
The results were quantified by densitometric analysis 
using the Image-Quant software. All Western blot 
experiments were performed in triplicate.
Statistical analysis 
Data was expressed as the mean ± SE and evaluated 
statistically using One-way ANOVA with SPSS (version 
19.0) software. A value of P < 0.05 was considered to 
be statistically significant. 
Results
Insulin resistant adipocytes assessment
Compared to the normal group, the glucose consump-
tion and glucose uptake of the insulin resistant group 
was decreased by 50.6% [(17.34 ± 1.20) vs. (8.56 ± 0.73) 
mmol/L, P < 0.01] and 57.9% (P < 0.01) respectively, 
indicating that the insulin resistant 3T3-L1 adipocytes 
model was conducted successfully.
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Impacts of CTRP3 on the glucose consumption of 
insulin resistant 3T3-L1 adipocytes
With the increasing concentrations of CTRP3 (10, 50, 
250, and 1,250 ng/mL), the glucose consumption was in-
creased by 22.1%, 42.9%, 76.6% and 80.5% respectively 
(all P < 0.01) compared to that of the control group. The 
differences of glucose consumption among 10 ng/mL, 
50 ng/mL and 250 ng/mL CTRP3 intervention groups 
were also significant (P < 0.05 or P < 0.01). There was no 
significant difference in glucose consumption between 
the 1,250 ng/mL and the 250 ng/mL CTRP3 intervention 
groups (P > 0.05), indicating that 250 ng/mL might be 
the optimal concentration of CTRP3 in promoting insu-
lin resistant 3T3-L1 adipocytes to utilise glucose (Fig. 1).
Impacts of CTRP3 on the glucose uptake  
of insulin resistant 3T3-L1 adipocytes
The dose-effect relationship of CTRP3 on glucose 
uptake
Compared to the control group, the glucose uptake in 
the CTRP3 intervention group at the concentrations of 
10, 50, 250, and 1,250 ng/mL was increased by 39.0%, 
68.0%, 108.0% and 111.0% respectively (all P < 0.01). 
The differences of glucose uptake among the CTRP3 
intervention groups at the concentrations of 10 ng/mL, 
50 ng/mL and 250 ng/mL were also significant (all 
P < 0.01). There was no significant difference in glucose 
uptake between the 1,250 ng/mL and the 250 ng/mL 
CTRP3 intervention groups (F = 0.343, P = 0.735), 
indicating that 250 ng/mL might be the optimal con-
centration of CTRP3 in improving insulin resistance in 
insulin resistant 3T3-L1 adipocytes (Table I).
The time-effect relationship of CTRP3 on glucose 
uptake
To investigate the time-effect relationship of CTRP3 
on glucose uptake in insulin resistant adipocytes, this 
research detected the glucose uptake in the 250 ng/mL 
CTRP3 intervention group at different times (0, 2, 6, 12, 
and 24h). Compared to 0h, the glucose uptake at 2h, 
6h, 12h and 24h was increased by 23.0%, 79.0%, 109.0% 
and 114.0% respectively (all P < 0.01). With the inter-
vention duration extended from 2h to 12h, the glucose 
uptake was also increased accordingly. There was no 
significant difference in glucose uptake at 12h and 24h 
(P > 0.05), indicating that the effects of CTRP3 inter-
vention at the concentration of 250 ng/mL for 12h on 
glucose uptake in insulin resistant 3T3-L1 adipocytes 
might be the maximal (Fig. 2).
Figure 1. Impacts of CTRP3 on the glucose consumption of insulin 
resistant 3T3-L1 adipocytes (mean ± SE). 
1–7: Normal group, Insulin resistance control group, 10 ng/mL 
CTRP3 intervention group, 50 ng/mL CTRP3 intervention 
group, 250 ng/mL CTRP3 intervention group, 1,250 ng/mL 
CTRP3 intervention group, 250 ng/mL CTRP3 + wortmannin 
intervention group vs. Insulin resistance control group *P < 0.01; 
vs. 250 ng/mL CTRP3 intervention group #P < 0.01
Rycina 1. Wpływ białka CTRP3 na zużycie glukozy przez 
insulinooporne adipocyty 3T3-L1 (średnia ± SE)
Table I. The dose-effect relationship of CTRP3 on glucose uptake of insulin resistant 3T3-L1 adipocytes (mean ± SE)
Tabela I. Zależność efektu od dawki białka CTRP3 w ocenie wychwytu glukozy insulinoopornych adipocytów 3T3-L1 (średnia ± SE)
CTRP3 content [ng/mL] 0 10 50 250 1,250 250∆
Glucose uptake (n = 9) 1 1.39 ± 0.11* 1.68 ± 0.13* 2.08 ± 0.19* 2.11 ± 0.18* 1.15 ± 0.08#
∆pretreated with 100 nmol/L wortmannin for 20 min. vs. CTRP3 content 0 *P < 0.01, vs. CTRP3 content 250 #P < 0.01
Figure 2. The time-effect relationship of CTRP3 on glucose uptake 
ratio of insulin resistant 3T3-L1 adipocytes (mean ± SE). * vs. 
Time 0 P < 0.01.
Rycina 2. Zależność efektu od czasu ekspozycji na działanie 
białka CTRP3 w ocenie współczynnika wychwytu glukozy 
insulinoopornych adipocytów 3T3-L1 (średnia ± SE)
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Impacts of CTRP3 on the expression and release 
of inflammation factors of insulin resistant  
3T3-L1 adipocytes
Compared to the control group, the content of TNF-α 
in the culture media of CTRP3 (10, 50, 250 ng/mL, 
for 12h) intervention group was decreased by 7.6% 
(F = 1.625, P = 0.124), 13.0% (P < 0.05) and 17.4% 
(P < 0.01) respectively; the content of IL-6 was decreased 
by 7.1%, 12.4% and 17.1% respectively (all P < 0.01); 
the mRNA relative expression of TNF-α was decreased 
by 8.0%, 16.0% and 26.0% respectively (all P < 0.01 or 
P < 0.05); and the mRNA relative expression of IL-6 
was decreased by 9.0%, 11.0% and 19.0% respectively 
(all P < 0.01 or P < 0.05) (Figs. 3 and 4).
Impacts of CTRP3 on the expression of insulin 
signal molecules of insulin resistant 3T3-L1 
adipocytes
Compared to the control group, with increases to the 
content of CTRP3 (10, 50, 250 ng/mL) treated for 12h, 
the protein relative expression of PI3K was increased 
by 0.63-, 1.00- and 1.36-fold respectively (all P < 0.01), 
and PKB(ser437) increased by 0.65-, 1.61- and 1.93-fold 
respectively (all P < 0.01). The difference among the 
CTRP3 intervention groups was also significant (all 
P < 0.01) (Fig. 5).
Impacts of CTRP3 on the expression of GLUT-4  
of insulin resistant 3T3-L1 adipocytes
Compared to the control group, with increases to 
the content of CTRP3 (10, 50, 250ng/mL) treated for 
12h, the mRNA relative expression of GLUT-4 was 
increased by 23.0%, 47.0% and 62.0% respectively 
(all P < 0.01),which may be the direct reason for the 
increasing glucose uptake with CTRP3 intervention 
(Fig. 4).
Impacts of wortmannin on the glucose  
consumption, glucose uptake and insulin signal 
transduction of insulin resistant 3T3-L1  
adipocytes with 250 ng/mL CTRP3 intervention
Compared to the insulin resistant 3T3-L1 adipocytes 
treated with 250 ng/mL CTRP3, the glucose consump-
tion, glucose uptake, PI3K protein relative expression, 
PKB (ser437) protein relative expression and GLUT-4 
mRNA relative expression in the 250 ng/mL CTRP3 
treated insulin resistant 3T3-L1 adipocytes pretreated 
with wortmannin was decreased by 53.2%, 44.7%, 
43.4%, 56.1 and 30.9% respectively (all P < 0.01), indi-
cating that CTRP3 may increase insulin sensitivity of 
Figure 3. Impacts of CTRP3 on the release of TNF-α and IL-6 of insulin resistant 3T3-L1 adipocytes (mean ± SE). 
1–5: Control group, 10 ng/mL CTRP3 intervention group, 50 ng/mL CTRP3 intervention group, 250 ng/mL CTRP3 intervention group, 
250 ng/mL CTRP3 + wortmannin intervention group. vs. control group *P < 0.01, ‡P < 0.05; vs. 250 ng/mL CTRP3 intervention 
group #P < 0.01
Rycina 3. Wpływ białka CTRP3 na uwalnianie TNF-α i IL-6 przez insulinooporne adipocyty 3T3-L1 (średnia ± SE)
Figure 4. Impacts of CTRP3 on the relative expression of TNF-α, 
IL-6 and GLUT-4 mRNA of insulin resistant 3T3-L1 adipocytes 
(mean ± SE). vs. control group * P < 0.01, ‡P < 0.05; vs. 
250 ng/mL CTRP3 intervention group # P < 0.01
Rycina 4. Wpływ białka CTRP3 na względną zmianę ekspresji 
TNF-α, IL-6 i mRNA GLUT-4 w insulinoopornych adipocytach 
3T3-L1 (średnia ± SE)
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insulin resistant 3T3-L1 adipocytes through PI3K signal 
transduction (Table I, Figs. 1, 3, 4, 5).
Discussion
CTRP3, a paralogue of adiponectin, is a member of the 
C1q and tumour necrosis factor (TNF)-related protein 
(CTRP) superfamily. It is expressed at high levels in 
adipose tissue and has recently emerged as a novel 
adipokine. Recombinant CTRP3 reduced glucose out-
put in cultured rat hepatoma cells by suppressing glu-
coneogenic genes, significantly inhibited LPS-induced 
IL-6 and TNF-a secretion in THP-1 cells, and reduced 
NF-kB p65 activity [4–8]. Clinical research indicated 
that circulating CTRP3 concentration had a significant 
association with cardiometabolic risk factors, such as 
obesity, glucose levels, lipid parameters, eGFR, and 
adiponectin levels [11]. These results suggested that 
CTRP3 may have anti-diabetic and anti-inflammatory 
properties. Chronic low-grade inflammation was 
thought to be the key in the pathogenesis of insulin 
resistance, T2DM and cardiovascular disease (CVD) 
[12]. As CTRP3 can inhibit inflammation, it is possible 
for CTRP3 to improve insulin resistance. But there no 
report has addressed this issue. So this study aimed to 
investigate the effects and mechanisms of CTRP3 on the 
insulin resistance of insulin resistant 3T3-L1 adipocytes.
Our research found that treatment with CTRP3 
significantly improved the glucose consumption and 
glucose uptake in insulin resistant 3T3-L1 adipocytes, 
suggesting that CTPR3 may increase the insulin sen-
sitivity of insulin resistant adipocytes. It also showed 
that the optimal concentration of CTRP3 intervention 
was 250 ng/mL, and the optimal time was 12h. To the 
best of our knowledge this is the first report into the 
impacts of CTRP3 on insulin sensitivity, and the optimal 
concentration as well as duration of CTRP3 treatment 
on insulin resistant adipocytes.
Elevated serum-free fatty acid (FFA) levels induce 
insulin resistance in animals and humans. To use FFA 
to construct an insulin resistant model either in vivo or 
in vitro is a classic and universal method [13]. In this 
research, we used palmitic acid incubation to construct 
insulin resistant 3T3-L1 adipocytes model according 
to a previous report [13]. We found that compared 
to normal adipocytes, the glucose consumption of 
palmitic acid incubated adipocytes was decreased 
by 50.6% [(17.34 ± 1.20) vs. (8.56 ± 0.73) mmol/L, 
P < 0.01] , indicating that the palmitic acid incubated 
3T3-L1 adipocytes could be considered as insulin resist-
ant adipocytes. 
From previous studies, it is well established that 
when there is an expansion of adipose tissue, there is 
a sustained inflammatory response accompanied by 
adipokine dysregulation, which leads to chronic sub-
clinical inflammation as well as insulin resistance [14]. 
One of the mechanisms leading to insulin resistance is 
chronic low-grade inflammation that involves a number 
of protagonists such as inflammatory cytokines, lipids 
and their metabolites, reactive oxygen species (ROS) 
and endoplasmic reticulum stress [15]. As mentioned 
above, CTRP-3 inhibits LPS-induced IL-6 and TNF-α 
release in human monocytes [5]. This research found 
that under the treatment with CTRP3 for 12h (10, 50, 
250 ng/mL), the release of TNF-α was decreased by 
7.6% (F = 1.625, P = 0.124), 13.0% (P < 0.05) and 17.4% 
(P < 0.01) respectively; the release of IL-6 was decreased 
by 7.1%, 12.4% and 17.1% respectively (all P < 0.01); 
and the mRNA relative expression of IL-6 and TNF-α 
had the same tendency. This indicates that CTRP3 could 
also inhibit inflammation in insulin resistant adipocytes, 
by which means CTRP3 increases insulin sensitivity of 
insulin resistant adipocytes.
Insulin resistance is a pathological condition that 
arises when insulin signalling is impaired, forcing 
pancreatic β-cells to produce more insulin in order to 
compensate for body demands and to maintain glucose 
homeostasis [16]. Insulin signalling involves a complex 
signalling cascade downstream of the insulin recep-
tor. This signalling cascade branches into two main 
pathways. The first is the PI3K/PKB pathway which is 
Figure 5. Impacts of CTRP3 on the relative expression of PI3K and 
PKB protein of insulin resistant 3T3-L1 adipocytes (mean ± SE). 
1–5: Control group, 10 ng/mL CTRP3 intervention group, 50 ng/
mL CTRP3 intervention group, 250 ng/mL CTRP3 intervention 
group, 250 ng/mL CTRP3 +wortmannin intervention group. 
vs. control group * P < 0.01, ‡P < 0.05; vs. 250 ng/mL CTRP3 
intervention group # P < 0.01
Rycina 5. Wpływ białka CTRP3 na względną zmianę ekspresji 
PI3K i PKB w insulinoopornych adipocytach 3T3-L1 (średnia 
± SE)
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largely responsible for insulin action on glucose uptake, 
as well as other metabolic actions of insulin, includ-
ing the suppression of gluconeogenesis. The second 
pathway is the Ras-mitogen-activated protein kinase 
(MAPK) pathway which mediates gene expression, but 
also interacts with the PI3K/PKB pathway to control 
cell growth and differentiation [17]. This article mainly 
focused on the PK3K/PKB signalling, and found that as 
the content of CTRP3 (10, 50, and 250 ng/mL) treatment 
increased, the protein relative expression of PI3K was 
increased by 0.63-, 1.00- and 1.36-fold respectively (all 
P < 0.01), and PKB(ser437) increased by 0.65-, 1.61- and 
1.93- folds- respectively (all P < 0.01), the mRNA relative 
expression of GLUT-4 was increased by 23.0%, 47.0% 
and 62.0% respectively (all P < 0.01), which may be 
the direct reason for the increased glucose uptake with 
CTRP3 intervention. 
To determine the role of insulin signal molecule 
PI3K in the effects of CTRP3 on insulin resistant adipo-
cytes, we also used wortmannin, the special inhibitor 
of PI3K, to pretreat adipocytes before the treatment 
with 250 ng/mL CTRP3. We found that the glucose 
consumption, glucose uptake, PI3K protein relative 
expression, PKB(ser437) protein relative expression and 
GLUT-4 mRNA relative expression in the adipocytes 
pretreated with wortmannin was decreased by 53.2%, 
44.7%, 43.4%, 56.1 and 30.9% respectively (all P < 0.01), 
indicating that CTRP3 may increase insulin sensitivity 
of insulin resistant 3T3-L1 adipocytes through PI3K 
signal transduction.
Insulin and inflammation signalling are intertwined. 
Jun N-terminal kinase-1 (JNK1) and inhibitor of kB 
kinase (IKKβ) are inflammatory signalling pathways 
which promote insulin resistance. Activation of either 
pathway leads to serine phosphorylation of insulin re-
ceptor substrate protein-1 (IRS-1), causing attenuation 
of insulin action [18]. This article found that CTRP3 
decreased the expression of inflammation factors of 
insulin resistant 3T3-L1 adipocytes and increased the 
expression of insulin signal molecules. So it is possible 
that the effects of CTRP3 on insulin signalling in 3T3-L1 
adipocytes may be just an indirect result following on 
from the inhibition of inflammation.
CTRP3 also regulates the expression and secretion 
of other adipokines, such as adiponectin. A dose of 
10 ng/mL CTRP3 increased adiponectin secretion in 
3T3-L1 adipocytes significantly [19]. As we all know, 
adiponectin is the most highly expressed and intensely 
studied adipokine and has insulin-sensitising, anti-
inflammatory and antiatherogenic properties [20]. So 
the modulation of the expression of other adipokines 
may be another mechanism for CTRP3 in increasing 
insulin sensitivity of 3T3-L1 adipocytes.
To sum up, this study found that CTRP3 may im-
prove insulin sensitivity of insulin resistant 3T3-L1 
adipocytes by decreasing inflammation and ameliorat-
ing insulin signalling, indicating that CTRP3 could be a 
new target for the prevention and cure of insulin resist-
ance and T2DM. But this study could not answer how 
CTRP3 decreases inflammation and improves insulin 
signalling, whether the impact is direct or indirect, and 
whether the effects still exist in vivo.
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